Literature DB >> 19423359

The Brazilian vaccine manufacturers' perspective and its current status.

Akira Homma1.   

Abstract

This article aims to give an overview of the current situation and perspectives for the Brazilian vaccine manufacturers, who play strong roles for developing countries in this field. The research, development and production of immunobiologicals in Brazil, especially vaccines for human use, is mainly supported by governmental institutions linked to the Ministry of Health as part of a strategy that prioritizes the public sector for access to vaccines and other biologicals that are regarded essential for the population. As a result, 83% of the vaccines required in 2007 were provided by national vaccine producers and only 17% were imported, mainly to reference centers for special vaccines that were used for special patients. Moreover, the country has actively exported yellow fever vaccine since 2002 and meningitis AC vaccine since 2007, having covered more than 60 nations. The perspectives have positively increased due to the government's policy of making internal investments, not only to avoid the external dependence of products for public health, but also to strengthen the Brazilian industrial sector related to biotechnology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423359     DOI: 10.1016/j.biologicals.2009.02.011

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  2 in total

1.  Access to new technologies in multipatented vaccines: challenges for Brazil.

Authors:  Cristina Possas; Adelaide Maria de Souza Antunes; Flavia Maria Lins Mendes; Suzanne de Oliveira Rodrigues Schumacher; Reinaldo Menezes Martins; Akira Homma
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

Review 2.  Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.

Authors:  Emma Rey-Jurado; Felipe Tapia; Natalia Muñoz-Durango; Margarita K Lay; Leandro J Carreño; Claudia A Riedel; Susan M Bueno; Yvonne Genzel; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-01-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.